Tadalafil Tablet, Film Coated
Product Images NDC 60290-029

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 60290-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Umedica Laboratories Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"image Description" (Tadalafil 10 mg 30s Bottle Label)

Label for Tadalafil Tablets, USP 10 mg oral film-coated tablets by Umedica Laboratories USA Inc. The label indicates the package contains 30 tablets. Drug is prescription-only. Includes storage instructions, manufacturer details from India, and packaging warnings.*

FDA Label Image

"image Description" (Tadalafil 20 mg 30s Bottle Label)

Label for Tadalafil Tablets, USP 20 mg, oral film-coated tablets. The package contains 30 tablets. Manufactured by Umedica Laboratories Pvt. Ltd., India, and distributed by Umedica Laboratories USA Inc. The label includes dosage and storage information, a barcode, and standard regulatory data such as GTIN, expiration, and lot number placeholders.*

FDA Label Image

"image Description" (Tadalafil 2pt5 mg 1000s Bottle Label)

Label for Tadalafil Tablets, USP 2.5 mg oral film-coated tablets from Umedica Laboratories USA Inc. The label includes storage instructions, warnings, usage directions, and manufacturer details. It states the product is made in India and distributed by Umedica Laboratories USA Inc. The package contains 1000 tablets. NDC 60290-027-02 is shown along with barcode and regulatory information.*

FDA Label Image

"image Description" (Tadalafil 5 mg 30s Bottle Label)

Label for Tadalafil Tablets, USP 5 mg, film-coated oral tablets. The package contains 30 tablets and is labeled for prescription use only (Rx only). Manufactured by Umedica Laboratories Pvt. Ltd., India, and distributed by Umedica Laboratories USA Inc. Storage instructions and other regulatory information are included.*

FDA Label Image

"image Description" (Tadalafil Figure 1)

A set of four line graphs showing the difference in blood pressure measurements (systolic and diastolic) between Tadalafil and placebo over 96 hours. The graphs compare standing and supine systolic and diastolic blood pressures, with time in hours on the x-axis and pressure difference in mmHg on the y-axis, including error bars indicating variability.*

FDA Label Image

"image Description" (Tadalafil Figure 2)

A line graph with two plots showing standing and supine systolic blood pressure (BP) changes in mmHg over 24 hours post-dose. The y-axis represents systolic BP changes, and the x-axis is time post-dose in hours. The graph compares effects of Tadalafil 20 mg with doxazosin 8 mg (solid line) and placebo with doxazosin 8 mg (dotted line).*

FDA Label Image

"image Description" (Tadalafil Figure 3)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo, combined with 8 mg doxazosin at 08:00. Four groups are plotted: 20 mg tadalafil at 08:00, placebo at 08:00, 20 mg tadalafil at 20:00, and placebo at 20:00. The graph tracks systolic BP changes relative to time post-dose.*

FDA Label Image

"image Description" (Tadalafil Figure 4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing for five consecutive days. The graph shows concentration peaks and decline over 120 hours with error bars representing variability.*

FDA Label Image

"image Description" (Tadalafil Figure 5)

A line graph showing change from baseline in IPSS Total Score over 12 weeks of treatment. Two lines represent Tadalafil 5 mg tablets and placebo. The Tadalafil line shows a greater decrease in score over time compared to placebo, with measurements at 0, 4, 8, and 12 weeks. Statistical significance (P < 0.01) is indicated.*

FDA Label Image

"image Description" (Tadalafil Figure 6)

Line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil tablets 5 mg and placebo. The graph shows greater score reduction with Tadalafil at all measured points, with statistical significance indicated at week 4 (P < 0.01). The x-axis represents treatment duration in weeks, and the y-axis represents the change from baseline score.*

FDA Label Image

"image Description" (Tadalafil Figure 7)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride combination to Placebo/Finasteride. The graph tracks changes at weeks 0, 4, 12, and 26, with Tadalafil/Finasteride showing greater decreases from baseline. Statistical significance markers indicate p-values at various points.*

FDA Label Image

"image Description" (Tadalafil Figure 8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between tadalafil tablets 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline in IPSS total score. The graph indicates a greater reduction in score with tadalafil 5 mg versus placebo, with statistical significance noted at p<0.01.*

FDA Label Image

"image Description" (Tadalafil Structure)

Chemical structure diagram of the active ingredient tadalafil, showing its molecular framework with multiple fused rings including indole and piperidine components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.